Dr. Mike Cahill, Ph. D.

Recorded 27 October 2023. A week after making my first video on this topic, after having seen only the presentation to Mexican Congress on 13th September, I have now seen more information on the mummies and still believe that they are more likely to be therapod dinosaurs than aliens. DNA analysis could resolve the issue if it appears. This is potentially one of the most important issues in human history. Have we been observed by another intelligent terrestrial species throughout our entire evolutionary history?

Critical analysis of one mainstream media news article on the "Mexican aliens" by the Australian Broadcasting Corporation, a member of the "Trusted News Initiative". They claim to offer proof that the bodies are not alien, but fail to do so. This is typical of mainstream 'debunking' following the narrative of "nothing to see here".

Dr. Cahill is a scientist with training in evolutionary theory, molecular cell biology and biochemistry, as well as 35 years research experience in industry and Universities on three continents. He presents a case that the "Mexican aliens" could be therapod dinosaurs. The birds are one lineage of therapod dinosaur to have survived the Cretaceous. These tridactyl creatures may be another.

I ordered the "Book Lies my Govt Told Me", by Robert M. Malone, from Amazon Australia. Today it arrived, with blank ruled pages inside. Censorship? You decide.

A short reply to Dr John Campbell's video of 5 November. https://www.youtube.com/watch?v=XzPophi-9MY, where Dr. Campbell commented on this paper: https://pubmed.ncbi.nlm.nih.gov/33176598/, which claims to have identified circulating SARS CoV-2 in Italy in September 2019.

In this video I note that the study design failed to take account of the hydrophobic nature of ivermectin, and the higher dose requirement to treat covid-19 than for treatment of parasites. This is because the covid target has different pharmacokinetics to the parasitic targets. I also present the argument the development of the Paxlovid covid antiviral may have been based upon the assumption of ivermectin efficacy. Paxlovid targets the same viral 3-chymotrypsin like protease enzyme that ivermectin inhibits. If cheap, safe and effective ivermectin is known to work, why develop new antivirals? I believe it is probably motivated by profit, and that is the reason that any information in favor of ivermectin's efficacy is discredited by the apparatus of power.

0:00 Introduction 0:00:44 Background 0:03:58 How I became involved (Germany, 2000-2007) 0:05:55 PGRMC1 phosphorylation in breast cancer 0:10:28 PGRMC1 induced before Hif-1-dependent hypoxia 0:14:23 A model for PGRMC1 phosphorylation 0:16:56 PGRMC1 affects cell survival to peroxide 0:20:32 2008 relocation to a regional Australian university: no national grant support 0:21:58 In my own interest: the following story is unique 0:22:17 Lack of Australian grant funding to me has retarded world science 0:23:07 I am available for strategic recruitment 0:23:27 PGRMC1 gained novel functions in the last eumetazoan common ancestor (LEUMCA) 0:24:24 The LEUMCA developed the first gastrulation organizer and novel cell types 0:28:33 PGRMC gained a new C-terminus and phosphorylated tyrosines with the LEUMCA 0:31:01 Y139 was inserted into the MAPR interhelical insertion region (MIHIR) 0:33:38 Y180 is part of the novel LEUMCA C-terminus 0:34:45 Y139 is present in a conserved putative amphiphilic helix 0:36:23 The MIHIR resembles a motif from multiple myosins 0:37:29 The MIHIR helix region has predicted coiled-coil propensity 0:38:14 In myosins the motif is in the coiled-coil region 0:39:19 Therefore PGRMC1 and myosins may interact with overlapping proteins 0:40:22 The MIHIR was inserted between heme interacting residues 0:41:43 Eumetazoan Y139 phosphorylation would prevent coiled-coils and recruit SH2 proteins 0:42:34 Eumetazoan Y180 phosphorylation would recruit SH2 domain proteins 0:43:22 Y139 is on the surface in the crystal structure 0:44:38 Proteins bound to PGRMC1 signal motifs could interact with each other 0:45:47 The MIHIR is not helical in the crystal structure 0:48:14 Protein binding to PGRMC1 could lead to signal activation 0:49:08 Mutation of Y180 module in cell culture (experiment design) 0:51:05 PGRMC1 phosphorylation mutants induce altered morphology 0:52:37 Proteomics on cell lines 0:53:15 Pathways analyses predict effects on metabolism and function 0:55:26 Verification of selected pathway differences 0:57:54 Proteomics conclusion of large effects on cells 0:58:14 PGRMC1 Y180 phosphorylation contributes to cancer growth 0:59:08 NAD homeostasis 1:00:21 PGRMC1 Y180 affects NAD/NNMT homeostatic pathways 1:01:34 PGRMC1 Y180 therefore implicated in aging biology 1:02:42 PGRMC1 implicated in circadian NAD regulation 1:03:43 From the literature both NNMT pathway and PGRMC1 affect stem cell pluripotency 1:04:53 I predict that PGRMC1 phosphorylation drives these effects 1:05:19 Eumetazoan embryology and stem cell biology 1:06:46 Chordates employ genomic CpG genetics during embryology 1:08:18 PGRMC1 is a master CpG epigenetic regulator 1:09:29 The Y180 TM exhibits CpG hypermethylation 1:10:07 Heat map and volcano plot of hypermethylated CpG markers due to Y180 mutation 1:10:54 CpG hypomethylation methylomics predicts that PI3K/Akt activity requires Y180 1:12:03 Pathways of Y180 hypomethylated markers predict stem cell and developmental biology 1:13:12 Hypothetical models of PGRMC1 phosphorylation is stem cells 1:14:47 Proposed PGRMC1 as cause of Alzheimer's disease 1:20:59 Summary 1:21:47 Model for PGRMC1 in eumetazoan embryo and stem cell biology 1:22:07 Collaborators and thanks to Ewa Goldys This 80 minute talk from 30 July 2022 (53 min played 1.5x) is for the public record and features slides I used in a 30 minute keynote talk at the Global Conference on Cell and Stem Cell Research, which I gave yesterday evening my time, on 29th July 2022. I have taken more time to elaborate important points in this talk. I've also supplemented the talk with some slides explaining how I got into this research field, so it takes a little longer. In the talk I argue that failure of the Australian grant system to support my work upon my return to Australia in 2008, after cofounding a German biotech company where I was Chief Research Officer (ProteoSys AG, 2000-2007), has probably retarded not just my own career. My research could have benefited the entire fields of cancer, stem cell biology, embryology, fertility, and neurobiology, worldwide. There are particular links to some economically important indication areas, including including Alzheimer's disease and possibly aging biology. I argue that my initial Australian grant proposals in 2009/2010 were rejected primarily because they were submitted from a regional university, despite the fact that I could have executed them, and they would have been spectacularly successful as the results I describe in this talk amply demonstrate. Once initial support is not given, the vicious cycle sets in as publication track record levels off due to lack of research funding. In my opinion, the intellectual property I brought with me from Germany to Australia in 2008 could have generated a substantial contribution to the Australian economy. That opportunity was squandered because of the failure of the Australian grant funding system to be able to recognise and support viable important research.

This was originally recorded on 24 January 2022 and uploaded to YouTube. It was removed by censorship from YouTube on the grounds that it contradicted WHO policy. It also contains a case that Pfizer based the design of its Paxlovid antiviral medication based upon knowledge of ivermectin mechanism of action. The original description from YouTube of 24 January: _____ In response to my previous video about ivermectin one acquaintance simply sent me the link to the Cochrane review on ivermectin, with the assumption that therefore any argument in favour of ivermectin would be invalid. I address that in this video.

This video was recorded 15 July 2022, and uploaded to Rumble 29 August 2022. With the current global spread of the SARS-Cov-2 Omicron variant it would be extremely desirable to have a low cost but effective treatment. In this video I argue that at least one treatment already exists, and has proven its efficacy in multiple countries. I discuss the slides of a talk that I presented via Zoom to the Faculty of Dentistry of Uruk University, Iraq, on 22 December, 2021. This video was recorded on 15 January, 2022.